Status:
COMPLETED
Open Label Study of TRx0014 in Alzheimer's Disease
Lead Sponsor:
TauRx Therapeutics Ltd
Conditions:
Alzheimer's Disease
Eligibility:
All Genders
Phase:
PHASE2
Brief Summary
This is an open label, dose-ranging study of two doses of TRx0014 in patients with mild or moderate Alzheimer's Disease. The trial is made available to any patient ongoing on treatment in the clinical...
Eligibility Criteria
Inclusion
- The patient may be of either sex and must be supervised by a carer who is competent to ensure compliance with the medication and who is willing to participate in completing the various assessments. The carer must provide written consent to his or her own participation in the study.
- Patients with capacity must give written informed consent to participate in this study. Patients who lack capacity to consent must be in agreement with entering into the study and have a personal legal representative giving written informed consent to their participation.
- The patient must have been ongoing in TRx-014-001 at time of study termination.
Exclusion
- There are no exclusion criteria. All patients taking medication at the termination of study TRx-014-001 and who wish to participate are eligible for recruitment.
Key Trial Info
Start Date :
September 13 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 2 2010
Estimated Enrollment :
111 Patients enrolled
Trial Details
Trial ID
NCT00684944
Start Date
September 13 2007
End Date
December 2 2010
Last Update
April 27 2018
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.